- Home
- DHY vs ZVRA Comparison
DHY vs ZVRA Comparison
Compare DHY & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DHY | ZVRA |
|---|---|---|
| Founded | N/A | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 208.3M | 472.9M |
| IPO Year | 1998 | 2015 |
Fundamental Metrics
Financial Performance| Metric | DHY | ZVRA |
|---|---|---|
| Price | $1.88 | $10.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | 645.8K | ★ 665.1K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 159.21 |
| EPS | N/A | ★ 1.35 |
| Revenue | N/A | ★ $106,470,000.00 |
| Revenue This Year | N/A | $37.27 |
| Revenue Next Year | N/A | $53.42 |
| P/E Ratio | ★ N/A | $7.65 |
| Revenue Growth | N/A | ★ 350.91 |
| 52 Week Low | $1.82 | $6.85 |
| 52 Week High | $2.16 | $13.16 |
Technical Indicators
Market Signals| Indicator | DHY | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 50.55 | 64.60 |
| Support Level | $1.83 | $8.29 |
| Resistance Level | $2.14 | $11.19 |
| Average True Range (ATR) | 0.03 | 0.39 |
| MACD | 0.00 | 0.08 |
| Stochastic Oscillator | 87.50 | 88.68 |
Price Performance
Historical ComparisonAbout DHY Credit Suisse High Yield Bond Fund
Credit Suisse High Yield Credit Fund is a diversified, closed-end management investment company. The Fund's principal investment objective is to generate current income. Capital appreciation is a secondary objective, pursued to the extent consistent with the Fund's primary income objective.
About ZVRA Zevra Therapeutics Inc.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.